The purpose of this study is to see if this plasma can be safely used in humans with COVID-19 and to see if it improves patients' health as compared to not using it in patients with pneumonia caused by SARS-CoV-2.
This open-label, randomized, controlled, phase 1 trial will assess the safety and efficacy of convalescent plasma in severely ill, hospitalized participants with pneumonia due to COVID-19. This study will enroll adults 18 years old and older, including pregnant women. A total of 80 eligible participants will be randomized to receive either 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 and standard of care (treatment arm) or standard of care alone (control arm). Participants in the treatment arm will receive 2 units of convalescent plasma on Study Day 1 in addition to standard of care. Participants will be assessed on study Day 1 (pre-dose), 30 minutes after each unit of plasma, on all Study Days while hospitalized, and Study Days 15, 22, 29, and 60. All participants will undergo a series of safety and efficacy, assessments. Blood samples will be collected on Days 1 (prior to plasma administration), 3, 8, 15, 29, and 60. Oropharyngeal or endotracheal samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8, 11, and 15.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
2 units of COVID-19 convalescent plasma compatible with their blood type
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
Participants With Serious Adverse Events.
Number of participants with at least one serious adverse events (SAEs) up to Study Day 29.
Time frame: Up to Study Day 29
Clinical Severity Score
Clinical Severity Score (CSC) measured by both survival time, time to recovery (defined by reaching levels 1-3 of the WHO modified 8-Point Ordinal Severity scale), and disease course while hospitalized and is calculated based on a procedure proposed by Shaw and Fay 2016 (https://doi.org/10.1002/sim.6950). CSC ranges from 1 to 57. Higher CSC is worse outcome. Clinical status assessment (WHO modified 8-Point Ordinal Severity scale) includes: 1. Not hospitalized, no limitations on activities. 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death
Time frame: Up to Study Day 29
Clinical Status Assessment, Time to Recovery
Time to recovery, defined by time needed to reach levels 1-3 using the WHO modified 8-Point Ordinal Severity scale assessed daily while hospitalized and on Day 15, 22, and 29: 1. Not hospitalized, no limitations on activities. 2. Not hospitalized, limitation on activities and/or requiring home oxygen; 3. Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 4. Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 5. Hospitalized, requiring supplemental oxygen; 6. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 7. Hospitalized, on invasive mechanical ventilation or ECMO; 8. Death
Time frame: Up to Study Day 29
National Early Warning Score (NEWS) Clinical Status Assessment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time to discharge or to a National Early Warning Score (NEWS) of ≤ 2 and maintained for 24 hours, whichever occurs first. NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29. Higher NEWS is worse, range from 0 to 20.
Time frame: Up to Study Day 29
Oxygenation
Days of supplemental oxygen while in hospital. defined as days with WHO8 ordinal score of 5, 6, or 7
Time frame: Daily while hospitalized and up to Study Day 29
Incidence of New Oxygenation Use up to Day 29
Incidence of new oxygenation use up to Day 29.
Time frame: From enrollment to Day 29.
Duration of New Oxygen Use up to Day 29
Duration (days) of new oxygen use up to Day 29.
Time frame: From enrollment to Day 29.
Non-invasive Ventilation/High Flow Oxygen Days up to Day 29
Days of non-invasive ventilation/high flow oxygen up to Day 29 Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices
Time frame: Daily while in hospital to Study Day 29.
Number of Participants With at Least One Day on Non-invasive Ventilation/High Flow Oxygen up to Day 29
number of participants with at least one day on non-invasive ventilation/high flow oxygen Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices
Time frame: Daily while in hospital until Study Day 29
Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29
Days of non-invasive ventilation/high flow oxygen up to Day 29
Time frame: Daily while in hospital to Study Day 29.
Ventilator/ECMO Days to Day 29
Days of mechanical ventilation or ECMO use (having a WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO) during the study in hospital until study day 29.
Time frame: Daily while in hospital to Study Day 29
New Mechanical Ventilation or ECMO Use
number of subjects with new mechanical ventilation or ECMO use up to Day 29 since all subjects were not on mechanical ventilation or ECMO at baseline.
Time frame: From enrollment to Day 29.
Duration of New Mechanical Ventilation or ECMO
Days of new mechanical ventilation or ECMO use up to Day 29.
Time frame: Daily while in hospital to Study Day 29
Duration of Hospitalization
Duration (days) of first hospitalization. Time until death or discharge or Study Day 29
Time frame: To Study Day 29
Mortality
28 day mortality.
Time frame: 28 days from Study Day 1
Number of Subjects With SAEs Through Day 29
Number of subjects with SAEs through Day 29.
Time frame: Through Study Day 29
Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29
Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events (AEs) through Day 29.
Time frame: Through Study Day 29
Changes in WBC With Differential Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29
Changes in Hemoglobin Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29
Changes in Platelets Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29.
Changes in Creatinine Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29.
Changes in Glucose Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29.
Changes in Total Bilirubin Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29
Changes in ALT Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29
Changes in AST Measurement Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29.
Changes in PT Measurement Laboratory Through Day 29
Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value \> baseline lab value.
Time frame: Through Day 29.